The tumor suppressor gene P53 is mutated in almost half of head and neck cancers. The current work assessed the prognostic significance of P53 alteration in patients with squamous cell carcinoma of the oral tongue treated with a curative intent, its association with age at diagnosis (using 45 years as a cut point), and risk exposure as defined by tobacco and/or alcohol consumption.
Methods
P53 alteration was determined immunohistochemically in 45 patients with tongue cancer treated with a curative intent.
Results
P53 alteration occurred in 20 of 45 tumors (44%) and was more common among younger patients (58% versus 36% for younger versus older patients, respectively) and those lacking tobacco/alcohol exposure (53% versus 40% for “no-risk” and “risk” groups, respectively), but the differences were not statistically significant. With a median follow-up of 56 months, 5-year progression-free survival rates were 48% and 66% in patients with and without P53 detection, respectively (P = 0.22).
Conclusions
Despite a trend of a younger age at diagnosis in P53-altered tumors, results did not reach statistically significant differences. A trend of a worse clinical outcome with P53 alteration was noted.
American Cancer Society: Cancer statistics, 2005. CA Cancer J Clin, 55: 10–30, 2005.
2.
DayGL: Oral cavity and pharynx, in HarrasA, (editor in chief): Cancer rates, pp 175–178, USDHHS, Washington, DC, 1996.
3.
SarkariaJ.N., HarariPM: Oral tongue cancer in young adults less than 40 years of age: rationale for aggressive therapy. Head Neck, 16: 107–111, 1994.
4.
RiesL.A.G., EisnerM.P., KosaryC.L., HankeyB.F., MillerB.A., CleggM., MariottoA., FeuerE.J., EdwardsBK (Eds): Oral cavity and pharynx cancer survival rates. In: SEER cancer statistics review, 1975–2001. Tables and Graphs, table XIX-4, Natl Cancer Inst, Bethesda, MD, http://seer.cancer.gov/scr/1975_2001, 2004.
5.
KochW.M., LangoM., SewellD., ZahurakM., SidranskyD: Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope, 109: 1544–1551, 1999.
6.
Siegelmann-DanieliN., HanlonA., RidgeJ.A., PadmoreR., FeinD.A., LangerCJ: Oral tongue cancer in patients less than forty five years old: institutional experience and comparison with older patients. J Clin Oncol, 16: 745–753, 1998.
7.
LevineA: P53, the cellular gatekeeper for growth and division. Cell, 88: 323–331, 1997.
8.
HollsteinM., RiceK., GreenblattM.S., SoussiT., FuchsR., SorlieT., HovingE., Smith-SorensenB., MontesanoR., HarrisCC: Database of P53 somatic mutations in human tumors and cell line. Nucleic Acid Res, 22: 3551–3555, 1994.
9.
GreenblatM.S., BennettW.P., HollsteinM., HarrisC: Mutations in the P53 tumor suppressor genes: clues to cancer etiology and molecular pathogenesis. Cancer Res, 54: 4855–4878, 1994.
10.
CabelguenneA., BlonsH., DeWaziersI., CarnotF., HoullierA.M., SoussiT., BrasnuD., BeauneP., LaccourreyeO., Laurent-PuigP: P53 alteration predicts tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol, 18: 1465–1474, 2000.
11.
TemanS., FlahaultA., PerieS., MonceauxG., CouletF., CallardP., BernaudinJ.F., St GuilyJ.L., FouretP: P53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J. Clin Oncol, 18: 385–394, 2000.
12.
BrennanJ.A., BoyleJ.O., KochW.M., GoodmanS.N., HrubanR.H., EbyY.J., CouchM.J., ForastiereA.A., SidranskyD: Association between cigarette smoking and mutation of the P53 gene in squamous cell carcinoma of the head and neck. N Engl J Med, 332: 712–717, 1995.
13.
RegeziJ.A., DekkerN.P., McMillanA., Ramirez-AmadorV., Meneses-GarciaA., Ruiz-Godoy RiveraL.M., ChrysomaliE., NgIO: P53, P21, Rb and MDM2 proteins in tongue carcinoma from patients <35 versus >75 years. Oral Oncol, 35: 379–383, 1999.
14.
ShigaH., HealthE.I., RasmussenA.A., TrockB., JohnstonP.G., ForastiereA.A., LangmacherM., BaylorA., LeeM., CullenKJ: Prognostic value of P53, glutathione S-transferase pi and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res, 5: 4097–4104, 1999.
15.
AlsnerJ., SorensenS.B., OvergaardJ: TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol, 59: 179–185, 2001.
16.
BadarccoG., VenutiA., BartolazziA., MorelloR., MarzettiF., MarcanteML: Overexpression of P53 and Bcl-2 proteins and the presence of HPV infection are dependent events in head and neck cancer. J Oral Pathol Med, 29: 173–179, 2000.
17.
ObataA., EuraM., SasakiH., SayaH., ChikamatsuK., TadaM., IggoR.D., YumotoE: Clinical significance of P53 function loss in squamous cell carcinoma of the oropharynx. Int J Cancer, 89: 187–193, 2000.
18.
HogmoA., Borresen-DaleA.L., BlegenH., LindholmJ., KuylenstiernaR., AuerG., Munck-WiklandE: TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas. Anticancer Res, 19: 3433–3438, 1999.
19.
SittelC., RuizS., VollingP., KvasnickaH.M., JungehulsingM., EckelHE: Prognostic significance of Ki-67, PCNA and P53 in cancer of the oropharynx and oral cavity. Oral Oncol, 35: 583–589, 1999.
20.
MelhemM.F., LawJ.C., El-AshmawyL., JohnsonJ.T., LandreneauP.J., SirvastavaS., WhitesideTL: Assessment of sensitivity and specificity of immunohistochemical staining of P53 in lung and head and neck cancers. Am J Pathol, 146: 1170–1177, 1995.
21.
WarnakuasuriyaS., JiaC., JohnsonN., HoughtonJ: P53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy. J Pathol, 191: 33–38, 2000.
22.
ChiangC.P., LangM.J., LiuB.Y., WangJ.T., LeuJ.S., HahnL.J., KuoMY: Expression of P53 protein in oral submucous fibrosis, oral epithelial hyperkeratosis and oral epithelial dysplasis. J Formos Med Assoc, 99: 229–234, 2000.
23.
LingenM.W., ChangK.W., McMurrayS.J., SoltD.B., KiesM.S., MittalB.B., HainesG.K., PeizerHJ: Overexpression of P53 in squamous cell carcinoma of the tongue in young patients with no known risk factors is not associated with mutations in exons 5–9. Head Neck, 22: 328–335, 2000.
24.
BaasI.O., MulderJ.W.R., OfferhousJ.A., VogelsteinB., HamiltonSR: An evaluation of six antibodies for immunohistochemistry of mutated P53 gene product in archival colorectal neoplasms. J Pathol, 172: 5–12, 1994.
25.
NagyB., TiszlaviczL., EllerJ., MolnarJ., ThurzoL: Ki-67, Cyclin d1, p53 and Bcl-2 expression in advanced head and neck cancer. In Vivo, 17: 93–96, 2003.
26.
WreesmannV., SheW., ThalerH.T., PoluriA., KrausD.H., PfisterD., ShahaA.R., ShahJ.P., RaoP.H., SinghB: Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. J Clin Oncol, 22: 3965–3972, 2004.
